Reports
As the novel coronavirus (COVID-19) continues to spread across the world, our analysts are constantly tracking the impact of this rapidly evolving situation on the markets and the consumer purchase behaviours. Thus, our latest estimates and analysis about the current market trends and forecast will exhaustively reflect the effects of this emerging pandemic.
Global Biosimilar Market: By Molecule; By Type of Manufacturing; By Indication; Regional Analysis; Historical Market and Forecast (2016-2026); Market Dynamics; Biosimilar Patent Landscape; Value Chain Analysis; Requirements for Setting Up a Biosimilar Manufacturing Plant; Competitive Landscape; Industry Events and Developments
Global Biosimilar Market Outlook
The global biosimilar market size reached a value of almost USD 5.3 billion in the year 2020. The biosimilar market is further expected to grow at a CAGR of 32% between 2021 and 2026 to reach a value of almost USD 28 billion by 2026.
Read more about this report - REQUEST FREE SAMPLE COPY IN PDF
The global biosimilar market has Europe as the leading region, accounting for about more than half of the global market share. The industry is led by the increasing number of ageing population within Europe. Following Europe, the United States, Japan, India, and South Korea are the other significant markets for biosimilar.
Properties and Applications
Biosimilars, variously known as subsequent entry biologics (SEBs) or follow-on biologics, are referred to as the FDA-approved biotherapeutic products that are similar to their reference biologics. It can only be manufactured after the expiration of the patent of the reference product.
Read more about this report - REQUEST FREE SAMPLE COPY IN PDF
The biosimilar market is divided on the basis of molecule into:
- Infliximab
- Insulin Glargine
- Epoetin Alfa
- Etanercept
- Filgrastim
- Somatropin
- Rituximab
- Follitropin Alfa
Presently, infliximab dominates the industry, accounting for the largest share in the industry.
On the basis of type of manufacturing, the biosimilar market is segmented into:
- In-house Manufacturing
- Contract Manufacturing
Among all of these, in-house manufacturing holds the majority of the share of the industry.
On the basis of indication, the biosimilar market is divided into:
- Auto-Immune Diseases
- Blood Disorder
- Diabetes
- Oncology
- Growth Deficiency
- Female Infertility
Amongst these, autoimmune diseases account for the majority of the total biosimilar market share.
The report also covers the major regions for biosimilar like North America, Europe, the Asia Pacific, Latin America, and the Middle East and Africa.
Read more about this report - REQUEST FREE SAMPLE COPY IN PDF
Market Analysis
The global biosimilar market is driven by the increasing demand for the product in the recent years owing to the help they provide in reducing the total cost of the treatment for a range of chronic diseases, such as autoimmune diseases, cancers, growth hormone deficiency, kidney failure, diabetes, infectious diseases, rheumatoid arthritis, haematological disorders, diabetes, CVDs, etc. The industry is further aided by the expiration of the patents of numerous blockbuster biologic drugs and a number of blockbuster drugs that are yet to lose patent protection in the forecast period, as it will boost the opportunities for manufacturers within the biosimilar industry for future.
The governments and third-party payers are undertaking cost-saving initiatives to encourage the use of biosimilars in place of branded biologics. Consequently, propelling the biosimilar market growth. Several factors influencing the industry include cost-effectiveness and the rising geriatric population. The industry may find hindrance owing to the negative perception from physicians, lower price differential compared to small-molecule generics, and patent extensions, among others.
Competitive Landscape
The report gives a detailed analysis of the following key players in the global biosimilar market, covering their competitive landscape, capacity, and latest developments like mergers, acquisitions, and investments, expansions of capacity, and plant turnarounds:
- Pfizer Inc.
- Celltrion Inc.
- Novartis AG
- Merck Sharp & Dohme Corp.,
- Eli Lilly and Company.
- Samsung Bioepis
- Accord-UK Ltd.
- Others
The comprehensive EMR report provides an in-depth assessment of the industry based on the Porter's five forces model along with giving a SWOT analysis.
| REPORT FEATURES | DETAILS |
|---|---|
| Base Year | 2020 |
| Historical Period | 2016-2020 |
| Forecast Period | 2021-2026 |
| Scope of the Report | Historical and Forecast Trends, Industry Drivers and Constraints, Historical and Forecast Market Analysis by Segment- Molecule, Type of Manufacturing, Indication, Region |
| Breakup by Molecule | Infliximab, Insulin Glargine, Epoetin Alfa, Etanercept, Filgrastim, Somatropin, Rituximab, Follitropin Alfa |
| Breakup by Type of Manufacturing | In-house Manufacturing, Contract Manufacturing |
| Breakup by Indication | Auto-Immune Diseases, Blood Disorder, Diabetes, Oncology, Growth Deficiency, Female Infertility |
| Breakup by Region | North America, Europe, Asia Pacific, Latin America, Middle East and Africa |
| Market Dynamics | SWOT, Porter's Five Forces, EMR’s Key Indicators for Price and Demand |
| Price Analysis | Historical and Forecast Price Trends- Regional |
| Competitive Landscape | Market Structure, Company Profiles- Company Overview, Product Portfolio, Demographic Reach and Achievements, Certifications |
| Companies Covered | Pfizer Inc., Celltrion Inc., Novartis AG, Merck Sharp & Dohme Corp.,, Eli Lilly and Company., Samsung Bioepis, Accord-UK Ltd., Others |
| Report Price and Purchase Option | Explore our purchase options that are best suited to your resources and industry needs. |
| Delivery Format | Delivered as an attached PDF and Excel through email, with an option of receiving an editable PPT, according to the purchase option. |
*We at Expert Market Research always thrive to give you the latest information. The numbers in the article are only indicative and may be different from the actual report.
1 Preface
2 Report Coverage – Key Segmentation and Scope
3 Report Description
3.1 Market Definition and Outlook
3.2 Properties and Applications
3.3 Market Analysis
3.4 Key Players
4 Key Assumptions
5 Executive Summary
5.1 Overview
5.2 Key Drivers
5.3 Key Developments
5.4 Competitive Structure
5.5 Key Industrial Trends
6 Snapshot
6.1 Europe
6.2 Regional
7 Industry Opportunities and Challenges
8 Global Biosimilar Market Analysis
8.1 Key Industry Highlights
8.2 Global Biosimilar Historical Market (2016-2020)
8.3 Global Biosimilar Market Forecast (2021-2026)
8.4 Global Biosimilar Market by Molecule
8.4.1 Infliximab
8.4.1.1 Market Share
8.4.1.2 Historical Trend (2016-2020)
8.4.1.3 Forecast Trend (2021-2026)
8.4.2 Insulin Glargine
8.4.2.1 Market Share
8.4.2.2 Historical Trend (2016-2020)
8.4.2.3 Forecast Trend (2021-2026)
8.4.3 Epoetin Alfa
8.4.3.1 Market Share
8.4.3.2 Historical Trend (2016-2020)
8.4.3.3 Forecast Trend (2021-2026)
8.4.4 Etanercept
8.4.4.1 Market Share
8.4.4.2 Historical Trend (2016-2020)
8.4.4.3 Forecast Trend (2021-2026)
8.4.5 Filgrastim
8.4.5.1 Market Share
8.4.5.2 Historical Trend (2016-2020)
8.4.5.3 Forecast Trend (2021-2026)
8.4.6 Somatropin
8.4.6.1 Market Share
8.4.6.2 Historical Trend (2016-2020)
8.4.6.3 Forecast Trend (2021-2026)
8.4.7 Rituximab
8.4.7.1 Market Share
8.4.7.2 Historical Trend (2016-2020)
8.4.7.3 Forecast Trend (2021-2026)
8.4.8 Follitropin Alfa
8.4.8.1 Market Share
8.4.8.2 Historical Trend (2016-2020)
8.4.8.3 Forecast Trend (2021-2026)
8.5 Global Biosimilar Market by Type of Manufacturing
8.5.1 In-house Manufacturing
8.5.1.1 Market Share
8.5.1.2 Historical Trend (2016-2020)
8.5.1.3 Forecast Trend (2021-2026)
8.5.2 Contract Manufacturing
8.5.2.1 Market Share
8.5.2.2 Historical Trend (2016-2020)
8.5.2.3 Forecast Trend (2021-2026)
8.6 Global Biosimilar Market by Indication
8.6.1 Auto-Immune Diseases
8.6.1.1 Market Share
8.6.1.2 Historical Trend (2016-2020)
8.6.1.3 Forecast Trend (2021-2026)
8.6.2 Blood Disorder
8.6.2.1 Market Share
8.6.2.2 Historical Trend (2016-2020)
8.6.2.3 Forecast Trend (2021-2026)
8.6.3 Diabetes
8.6.3.1 Market Share
8.6.3.2 Historical Trend (2016-2020)
8.6.3.3 Forecast Trend (2021-2026)
8.6.4 Oncology
8.6.4.1 Market Share
8.6.4.2 Historical Trend (2016-2020)
8.6.4.3 Forecast Trend (2021-2026)
8.6.5 Growth Deficiency
8.6.5.1 Market Share
8.6.5.2 Historical Trend (2016-2020)
8.6.5.3 Forecast Trend (2021-2026)
8.6.6 Female Infertility
8.6.6.1 Market Share
8.6.6.2 Historical Trend (2016-2020)
8.6.6.3 Forecast Trend (2021-2026)
8.7 Global Biosimilar Market by Region
8.7.1 Market Share
8.7.1.1 North America
8.7.1.2 Europe
8.7.1.3 Asia Pacific
8.7.1.4 Latin America
8.7.1.5 Middle East and Africa
9 Regional Analysis
9.1 North America
9.1.1 Historical Trend (2016-2020)
9.1.2 Forecast Trend (2021-2026)
9.1.3 Breakup by Country
9.1.3.1 United States of America
9.1.3.2 Canada
9.2 Europe
9.2.1 Historical Trend (2016-2020)
9.2.2 Forecast Trend (2021-2026)
9.2.3 Breakup by Country
9.2.3.1 United Kingdom
9.2.3.2 Germany
9.2.3.3 France
9.2.3.4 Italy
9.2.3.5 Others
9.3 Asia Pacific
9.3.1 Historical Trend (2016-2020)
9.3.2 Forecast Trend (2021-2026)
9.3.3 Breakup by Country
9.3.3.1 China
9.3.3.2 Japan
9.3.3.3 India
9.3.3.4 ASEAN
9.3.3.5 Australia
9.3.3.6 Others
9.4 Latin America
9.4.1 Historical Trend (2016-2020)
9.4.2 Forecast Trend (2021-2026)
9.4.3 Breakup by Country
9.4.3.1 Brazil
9.4.3.2 Argentina
9.4.3.3 Mexico
9.4.3.4 Others
9.5 Middle East and Africa
9.5.1 Historical Trend (2016-2020)
9.5.2 Forecast Trend (2021-2026)
9.5.3 Breakup by Country
9.5.3.1 Saudi Arabia
9.5.3.2 United Arab Emirates
9.5.3.3 Nigeria
9.5.3.4 South Africa
9.5.3.5 Others
10 Market Dynamics
10.1 SWOT Analysis
10.1.1 Strengths
10.1.2 Weaknesses
10.1.3 Opportunities
10.1.4 Threats
10.2 Porter’s Five Forces Analysis
10.2.1 Supplier’s Power
10.2.2 Buyers Power
10.2.3 Threat of New Entrants
10.2.4 Degree of Rivalry
10.2.5 Threat of Substitutes
10.3 EMR’s Key Indicators for Demand
10.4 EMR’s Key Indicators for Price
11 Biosimilar Patent Landscape
11.1 Patent Landscape in the US
11.2 Patent Landscape in Europe
11.3 Patent Landscape in Japan
12 Value Chain Analysis
12.1 Characterizing the Existing Innovator Drug
12.2 Research and Development
12.2.1 Characterization of Biosimilars
12.2.2 Developing a Unique Cell Line
12.3 Product Development
12.3.1 Pre-Testing
12.3.2 Intermediary Clinical Testing (PK/PD)
12.3.3 Confirmatory Clinical Phase-III
12.4 Final Product Formulation
12.5 Marketing and Distribution
13 Price Analysis
13.1 North America Historical Price Trends (2016-2020) and Forecast (2021-2026)
13.2 Europe Historical Price Trends (2016-2020) and Forecast (2021-2026)
13.3 Asia Pacific Historical Price Trends (2016-2020) and Forecast (2021-2026)
13.4 Latin America Historical Price Trends (2016-2020) and Forecast (2021-2026)
13.5 Middle East and Africa Historical Price Trends (2016-2020) and Forecast (2021-2026)
14 Requirements for Setting Up a Biosimilar Manufacturing Plant
14.1 Manufacturing Process
14.2 Raw Material Requirements
14.3 Raw Material Pictures
14.4 Land and Construction Requirements
14.5 Machinery and Infrastructure Requirements
14.6 Machinery Pictures
14.7 Plant Layout
14.8 Packaging Requirements
14.9 Utility Requirements
14.10 Manpower Requirements
15 Competitive Landscape
15.1 Market Structure
15.2 Key Players’ Market Share
15.3 Company Profiles
15.3.1 Pfizer Inc.
15.3.1.1 Company Overview
15.3.1.2 Product Portfolio
15.3.1.3 Demographic Reach and Achievements
15.3.1.4 Financial Summary
15.3.1.5 Certifications
15.3.2 Celltrion Inc.
15.3.2.1 Company Overview
15.3.2.2 Product Portfolio
15.3.2.3 Demographic Reach and Achievements
15.3.2.4 Financial Summary
15.3.2.5 Certifications
15.3.3 Novartis AG
15.3.3.1 Company Overview
15.3.3.2 Product Portfolio
15.3.3.3 Demographic Reach and Achievements
15.3.3.4 Financial Summary
15.3.3.5 Certifications
15.3.4 Merck Sharp & Dohme Corp.,
15.3.4.1 Company Overview
15.3.4.2 Product Portfolio
15.3.4.3 Demographic Reach and Achievements
15.3.4.4 Financial Summary
15.3.4.5 Certifications
15.3.5 Eli Lilly and Company.
15.3.5.1 Company Overview
15.3.5.2 Product Portfolio
15.3.5.3 Demographic Reach and Achievements
15.3.5.4 Financial Summary
15.3.5.5 Certifications
15.3.6 Samsung Bioepis
15.3.6.1 Company Overview
15.3.6.2 Product Portfolio
15.3.6.3 Demographic Reach and Achievements
15.3.6.4 Financial Summary
15.3.6.5 Certifications
15.3.7 Accord-UK Ltd.
15.3.7.1 Company Overview
15.3.7.2 Product Portfolio
15.3.7.3 Demographic Reach and Achievements
15.3.7.4 Financial Summary
15.3.7.5 Certifications
15.3.8 Others
16 Events and Developments
List of Figures and Tables
1. Global Biosimilar Market: Key Industry Highlights, 2016 and 2026
2. Global Biosimilar Historical Market: Breakup by Molecule (USD Billion), 2016-2020
3. Global Biosimilar Market Forecast: Breakup by Molecule (USD Billion), 2021-2026
4. Global Biosimilar Historical Market: Breakup by Indication (USD Billion), 2016-2020
5. Global Biosimilar Market Forecast: Breakup by Indication (USD Billion), 2021-2026
6. Global Biosimilar Historical Market: Breakup by Type of Manufacturing (USD Billion), 2016-2020
7. Global Biosimilar Market Forecast: Breakup by Type of Manufacturing (USD Billion), 2021-2026
8. Global Biosimilar Historical Market: Breakup by Region (USD Billion), 2016-2020
9. Global Biosimilar Market Forecast: Breakup by Region (USD Billion), 2021-2026
10. North America Biosimilar Historical Market: Breakup by Country (USD Billion), 2016-2020
11. North America Biosimilar Market Forecast: Breakup by Country (USD Billion), 2021-2026
12. Europe Biosimilar Historical Market: Breakup by Country (USD Billion), 2016-2020
13. Europe Biosimilar Market Forecast: Breakup by Country (USD Billion), 2021-2026
14. Asia Pacific Biosimilar Historical Market: Breakup by Country (USD Billion), 2016-2020
15. Asia Pacific Biosimilar Market Forecast: Breakup by Country (USD Billion), 2021-2026
16. Latin America Biosimilar Historical Market: Breakup by Country (USD Billion), 2016-2020
17. Latin America Biosimilar Market Forecast: Breakup by Country (USD Billion), 2021-2026
18. Middle East and Africa Biosimilar Historical Market: Breakup by Country (USD Billion), 2016-2020
19. Middle East and Africa Biosimilar Market Forecast: Breakup by Country (USD Billion), 2021-2026
20. North America Historical Price Trends and Forecast 2016-2026
21. Europe Historical Price Trends and Forecast 2016-2026
22. Asia Pacific Historical Price Trends and Forecast 2016-2026
23. Latin America Historical Price Trends and Forecast 2016-2026
24. Middle East and Africa Historical Price Trends and Forecast 2016-2026
25. Global Biosimilar Market Structure
Key Questions Answered in the Report
In 2020, the global biosimilar market attained a value of nearly USD 5.3 billion.
In the forecast period of 2021-2026, the industry is projected to grow at a CAGR of 32%.
By 2026, the market is estimated to reach a value of about USD 28 billion.
The major drivers of the industry such as rising disposable incomes, increasing geriatric population, reduction in the cost of the treatment for chronic and autoimmune diseases, and the upcoming expiration of many blockbuster biologic patents are expected to aid the market growth.
The cost-saving initiatives by governments and third-party payers encouraging the use of biosimilars over branded biologics are the major trends expected to drive the market growth.
The major regions in the industry are North America, Europe, the Asia Pacific, Latin America, and the Middle East and Africa, with Europe accounting for the largest market share.
The leading molecule type in the industry is Infliximab.
The major manufacturing type in the market is in-house manufacturing.
Autoimmune diseases account for the leading market share among other indication types.
The key players in the industry are Pfizer Inc., Celltrion Inc., Novartis AG, Merck Sharp & Dohme Corp., Eli Lilly and Company, Samsung Bioepis, and Accord-UK Ltd., among others.
Analyst Review
The global biosimilar market attained a value of nearly USD 5.3 billion in 2020 driven by the growing occurrence of chronic and autoimmune diseases. Aided by the upcoming expiration of many blockbuster biologic patents, the market is expected to witness a further growth in the forecast period of 2021-2026, growing at a CAGR of 32%. The market is projected to reach USD 28 billion by 2026.
EMR’s meticulous research methodology delves deep into the market, covering the macro and micro aspects of the industry. Based on molecule, the biosimilar market is divided into Infliximab, Insulin Glargine, Epoetin Alfa, Etanercept, Filgrastim, Somatropin, Rituximab, and Follitropin Alfa, with Infliximab accounting for the largest share in the industry. On the basis of manufacturing type, the industry is bifurcated into in-house and contract manufacturing, with in-house manufacturing leading the market. Autoimmune diseases account for the largest market share based on indication. The major regional markets for biosimilar are North America, Europe, the Asia Pacific, Latin America, and the Middle East and Africa, with Europe accounting for the largest share of the market. The key players in the above industry include Pfizer Inc., Celltrion Inc., Novartis AG, Merck Sharp & Dohme Corp., Eli Lilly and Company, Samsung Bioepis, and Accord-UK Ltd., among others.
EMR’s research methodology uses a combination of cutting-edge analytical tools and the expertise of their highly accomplished team, thus, providing their customers with market insights that are accurate, actionable, and help them remain ahead of their competition.
Purchase Options
Call us on
Purchase Full Report
Mini Report
$1499
-
Selected Sections, One User
-
Printing Not Allowed
-
Email Delivery in PDF
-
Free Limited CustomisationPost Sales Analyst Support50% Discount on Next UpdateSingle User License
$2699-
All Sections, One User
-
One Print Allowed
-
Email Delivery in PDF
-
Free Limited CustomisationPost Sales Analyst Support50% Discount on Next UpdateFive User License
$3699-
All Sections, Five Users
-
Five Prints Allowed
-
Email Delivery in PDF
-
Free Limited Customisation
-
Post Sales Analyst Support
-
50% Discount on Next Update
Corporate License
$4699-
All Sections, Unlimited Users
-
Unlimited Prints Allowed
-
Email Delivery in PDF + Excel
-
Free Limited Customisation
-
Post Sales Analyst Support
-
50% Discount on Next Update
Contact AnalystAny Question? Speak With An Analyst
Request SampleView A Sample
Request CustomisationDid You Miss Anything, Ask Now
Why Expert Market Research?RIGHT PEOPLE
We are technically excellent, strategic, practical, experienced and efficient; our analysts are hand-picked based on having the right attributes to work successfully and execute projects based on your expectations.
RIGHT METHODOLOGY
We leverage our cutting-edge technology, our access to trusted databases, and our knowledge of the current models used in the market to deliver you research solutions that are tailored to your needs and put you ahead of the curve.
RIGHT PRICE
We deliver in-depth and superior quality research in prices that are reasonable, unmatchable, and shows our understanding of your resource structure. We, additionally, offer attractive discounts on our upcoming reports.
RIGHT SUPPORT
Our team of expert analysts are at your beck and call to deliver you optimum results that are customised to meet your precise needs within the specified timeframe and help you form a better understanding of the industry.
Similar Reports
The India biosimilar market size reached a value of almost USD 633 million in the year 2020. The market is further expected to grow at a CAGR of 11% between 2021 and 2026.
Prothrombin Complex Concentrate (PCC) Market Size, Share, Report 2021-2026
The global human insulin market attained USD 36 billion in 2020. The market is expected to grow at a CAGR of 4.7% in the forecast period of 2021-2026 to attain USD 48 billion by 2026.
The Europe biosimilar market attained a value of USD 2,945 million in the year 2020 driven by the growing geriatric population in the region. Aided by the low cost of the product and the expected expi...
The global tumour necrosis factor inhibitor drugs market attained a value of USD 40.3 billion in 2020, driven by the increased incidences of different inflammatory diseases. Aided by the development o...
NEWSLETTER